Increxxa™ (tulathromycin injection) approved by FDA for U.S. cattle and swine producers and veterinarians.
Elanco Animal Health Incorporated announced the U.S. FDA approval of Increxxa™ (tulathromycin injection) for the treatment of bovine respiratory disease (BRD) and swine respiratory disease (SRD).
“We recognize what a challenge respiratory disease can be for the livestock industry and are excited to offer Increxxa to veterinarians and producers, giving them yet another solution to help combat this problematic disease in cattle and swine,” said Jose Simas, executive vice president, U.S. farm animal business at Elanco. “Like all Elanco products, veterinarians and producers can be confident that Increxxa is held to the company’s uncompromising standard of potency, uniformity and quality.”
“Elanco is committed to offering a broad portfolio of products to keep livestock healthy,” Simas noted. “With the availability of Increxxa, producers now have another strong option to support the responsible use of antibiotics in their herds.”
INCREXXA FOR CATTLE AND SWINE
“BRD contributes to 40-50% of all cattle mortality,” said Dr. Brett Terharr, Elanco consulting veterinarian. “Studies consistently show tulathromycin, the active ingredient in Increxxa, helps decrease the negative effects of BRD, such as morbidity and mortality, when used metaphylactically. This can lead to more profits by avoiding return trips to the hospital pen and getting cattle back to the feedbunk.”
“The addition of Increxxa to Elanco’s portfolio continues to strengthen the tool chest against swine diseases in our modern production systems. Our product portfolio offers multiple active ingredients, multiple routes of administration and multiple label indications, leading to more innovative veterinarian-derived treatment and control options,” said Dr. Eric Christianson, Elanco consulting veterinarian.
